Molecular analysis of p53 and patched (PTCH), two candidate tumor suppressor genes for non-melanocytic skin cancer, was performed in skin tumors from six patients aected by the cancer-prone disease xeroderma pigmentosum (XP). UV-speci®c p53 mutations were detected at a frequency of 38 ± 50% in all the tumor types analysed, including melanomas. Additional analysis of PTCH mutations in the subset of eight basal call carcinomas (BCC) revealed a very high mutation frequency of this gene (90%) which exceeded that detected in the p53 gene in the same tumors (38%). PTCH mutations were predominantly UV-speci®c C4T transitions. This mutation pattern is dierent from that reported in BCC from normal donors where PTCH mutation frequency is 27% and mutations are frequently deletions and insertions. These ®ndings suggest that PTCH mutations represent an earlier event in BCC development than p53 alterations and that the inability of XP patients to repair UV-induced PTCH mutations might signi®cantly contribute to the early and frequent appearance of BCC observed in these patients. Oncogene (2000) 19, 463 ± 467.
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Keywords: skin cancer; XP; p53; PATCHED; UV light Mutations in a number of genes have been associated with the genesis of human skin cancer. The inactivation and/or mutation of the p53 gene has been implicated as an important factor in the pathogenesis of UV lightinduced non-melanocytic skin cancers (NMSC), i.e. basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). All p53 mutations detected in these tumors are indeed consistent with the mutagenic action of UV light as inferred from in vitro studies (reviewed in Dogliotti et al., 1998) . More recently, a set of members of the Sonic hedgehog (SHH) signaling pathway, which is required for correct embryonic patterning, have been shown to be directly and speci®cally involved in BCC development. In particular, inactivating mutations of patched (PTCH), a SHH receptor that acts negatively on this signaling pathway, have been found both in familial and sporadic BCC (reviewed in Gailani and Bale, 1997) . Other alterations in the same signaling pathway have also been reported in sporadic BCC, namely the activation of the transcription factor Gli1 in basal cells (Dahmane et al., 1997) and activating mutations of shh (Oro et al., 1997) and smoothened (smo) . Interestingly, the analysis of PTCH mutations in BCC shows that, dierently from what was observed in the p53 gene, almost half of the mutations identi®ed are frameshift mutations or rearrangements which are not typical of UV mutagenesis (Hahn et al., 1996; Johnson et al., 1996; Gailani et al., 1996; Unden et al., 1996; Chidambaram et al., 1996; Wolter et al., 1997; Wicking et al., 1997; Aszterbaum et al., 1998) . The role of UV radiation in the genesis of alterations of the PTCH gene is then questionable.
In addition to p53 and PTCH, other genes which control the susceptibility to skin cancer are those defective in the cancer-prone hereditary disorder xeroderma pigmentosum (XP). The biochemical defect in most XP patients (seven complementation groups designated XP-A to XP-G) is in the nucleotide-excision repair (NER), a versatile damage removal pathway that repairs UV-induced photoproducts (reviewed in de Laat et al., 1999) . A minority of XP cases, the so-called XP variant (XP-V) group, which show late onset and slow progression of clinical symptoms, are defective in the ability to synthesize intact daughter DNA strands after UV irradiation as a consequence of an alteration in trans-lesion bypass (Cordonnier et al., 1999) due to mutations in the human DNA polymerase Z (Masutani et al., 1999) .
In this study molecular analysis of p53 and PTCH genes was conducted in skin tumors from XP patients (either NER-defective or XP-V) to analyse the interplay among these skin cancer susceptibility genes in cancer development. Speci®cally, p53 mutations were analysed in dierent types of skin tumors (eight BCC, three SCC, four melanomas (MLM) and two keratocanthomas (KA)) to test whether the UV damage etiology might extend to cancers other than NMSC. In the subset of BCC both p53 and PTCH mutations were analysed to gain an insight into the cascade of genetic events that lead to this very common human neoplasia.
UV mutation signature is present in the p53 gene of dierent skin cancer types from XP patients Human skin cancer is often associated with alterations of the p53 gene (reviewed in Dogliotti et al., 1998) , with the exception of melanoma which present low incidence of p53 mutations (Lubbe et al., 1994; Papp et al., 1996) . Nucleotide sequence analysis of the conserved region (exon 5-8) of the p53 gene was performed in 17 skin tumors (eight BCC, three SCC, four MLM and two KA) from six XP patients, as described in D' Errico et al. (1997) . Tumor samples taken for the molecular analysis presented an estimated tumor cell content of 80% or more. When p53 mutations were identi®ed in the tumor sample, blood lymphocyte DNA from the same patient was analysed to check whether it contained the same mutation. The main clinical and genetic features of our XP patients are displayed in Table 1 . For each tumor, the histological diagnosis, the localization and the patient age at onset are listed in Table 2 . A high frequency of p53 mutations ranging between 38 ± 50% was detected independently of the tumor type (Table 2) . Mutations were also identi®ed in 2/4 MLM analysed. The mutation type revealed the typical UV mutation signature: all mutations were base pair substitutions, predominantly (7/9) C4T transitions at dipyrimidine sites and the 3'C in TC or CC sequences was the preferential target. One BCC sample (XP2-9244) presented two missense mutations 161 nt apart, likely derived from two unrepaired UV photoproducts, and a possible polymorphism (the same change was detected in normal DNA) at codon 257. This polymorphism is not among the common p53 polymorphisms (IARC UV-induced DNA repair (unscheduled DNA synthesis) was analyzed in in vitro cultured cells (®broblasts or keratinocytes) from unaected skin biopsies. XP1 and XP2 showed reduced cell survival after UV but normal level of UDS, as typically observed in XP-V patients. Procedures for cellular and genetic analysis are described in Stefanini et al. (1973) . In the case of patient XP6 only tumor DNA was available; 
htm).
A silent mutation located at a C residue within a nondipyrimidinic site was also detected in sample XP1-8394. In XP-V cells the UV-induced mutation spectrum is expected to contain a higher proportion of transversions, particularly C4A transversions, than is seen in normal human cells (Wang et al., 1993; McGregor et al., 1999) . One C4A transversion (XP2-9244) was identi®ed among our four XP-V p53 mutations but the small sample size limits the signi®cance of this observation. The premutagenic photoproducts in tumors from NER-defective patients (XP3, XP4 and XP5) were located exclusively on the nontranscribed strand whereas an even distribution between the two strands was observed in skin cancers from XP-V patients (XP1 and XP2). These observations, although limited by the small number of samples analysed, are in agreement with larger studies conducted either on cells (Wang et al., 1993) or on tumor DNA (Giglia et al., 1998; Dumaz et al., 1993) from XP patients. Remarkably, three of the mutated p53 codons (177, 196 and 278) coincide with the slow spots for UV damage repair identi®ed by Tornaletti and Pfeifer (1994) . The type and location of all p53 mutations detected in XP skin tumors strengthen the association between unrepaired or misreplicated UV photodamage and mutations in the p53 tumor suppressor gene. Whether p53 mutations are necessary events in skin cancer development is still an open question. Interestingly, among the four BCC derived from patient XP2, the two samples that were mutated in the p53 gene (see Table 2 ) developed at later age as compared to the wild-type p53 tumors. These ®ndings, together with previous observations of high frequency of p53 mutations in BCC from subjects chronically exposed to sunlight (D'Errico et al., 1997), suggest an association between cumulative sun exposure and occurrence of p53 mutations.
High frequency of PTCH mutations is present in BCC from XP patients: mutation type is consistent with UV mutagenesis Recently, mutations in the PTCH gene have been described in familial as well as sporadic BCC (reviewed in Gailani and Bale, 1997) . The eight BCC among our XP tumor samples were further analysed for the occurrence of PTCH mutations in the coding region (exon 2-22) as described in Hahn et al. (1996) . When PTCH mutations were identi®ed in the tumor sample, normal DNA from the same patient was analysed to check whether it contained the same mutation. As shown in Table 3 , 7/8 BCC analysed were mutated in the PTCH gene and four of them presented more than one alteration. An example of multiple mutations detected in the same tumor sample (XP5-1216) is shown in Figure  1 (B1 ± B4). A silent mutation at nucleotide position 1674 found in the two tumor samples XP1-11540 and XP5-1216 was also detected in the corresponding normal DNA ( Figure 1A2 and B2 ). This polymorphism has been previously described (Eklund et al., 1998) . Most of PTCH mutations were UV-speci®c base substitutions. In particular, 9/12 were C4T transitions at dipyrimidine sites. Among these transitions, one was a CC4TT tandem mutation, the hallmark of UV mutagenesis. The premutagenic photoproducts were located on the nontranscribed strand in BCC from NER-defective patients (XP3, XP4 and XP5) whereas mutations on both strands were detected in tumors from XP-V patients (XP1 and XP2). PTCH mutation type and distribution in BCC from XP patients was therefore consistent with UV mutagenesis. The remaining 25% of the PTCH mutations (3/12) were frameshift mutations. The frameshift mutation at codon 238 (exon 5) found in the tumor sample XP2-3807 causes a premature stop codon at position 251 within the ®rst large extracellular loop of PTCH. The two frameshift mutations within exon 16 detected in sample XP2-9244 created the same premature stop codon at position 944 in the second large extracellular loop of the protein. The frequency of deletions and insertions leading to truncated or absent protein appears to be lower in BCC from XP patients than in BCC from non-XP patients (68% and 38% in familial and sporadic BCC respectively).
The comparison of the data from p53 and PTCH mutation analysis (Table 3 , last column) shows that these two cancer susceptibility genes are both mutated in three out of the eight BCC analysed (38%). The remaining four samples were mutated only in PTCH suggesting that alterations in this gene are an earlier event in BCC development than p53 mutations.
The high level of mutations detected in the PTCH gene in BCC from XP patients deserves some comment. Mutations in this transmembrane protein have been originally described in patients with the nevoid basal call carcinoma (NBCCS), a hereditary disease characterized by multiple BCC and developmental abnormalities (Hahn et al., 1996) . Mutations in PTCH were later detected also in sporadic BCC at a frequency of 27% (90 BCC currently analysed) Unden et al., 1996; Wolter et al,. 1997; Wicking et al., 1997; Aszterbaum et al., 1998) . The type of mutations described in this gene resemble those found in most tumor-suppressor genes which are frequently deletions and insertions leading to truncated or absent protein product (the exception to this rule is in fact the p53 gene). These mutations constitute 68% of PTCH mutations found in familial BCC and 38% of mutations detected in sporadic BCC (Hahn et al., 1996; Johnson et al., 1996; Gailani et al., 1996; Unden et al., 1996; Chidambaram et al., 1996; Wolter et al., 1997; Wicking et al., 1997; Aszterbaum et al., 1998) . The frequency and type of PTCH mutations detected in BCC from our XP patients appeared to be dierent from those described in non-XP BCC. First, PTCH mutations in XP BCC were very frequent: all except one of the BCC analysed presented single or multiple mutations within this gene. Second, the type of mutations were predominantly UV-speci®c single base pair substitutions (75%). It is likely that PTCH mutations in the normal population arise via diverse mechanisms including sunlight-induced mutagenesis. In a genetic background that is defective in the processing of UV photolesions, like XP cells, UV-induced mutations might become predominant in the genesis of PTCH functional alterations. This model is further supported by the results of a recent study in a dierent sample of BCC from XP patients (Bodak et al., 1999) .
What is the chain of genetic events that lead to the development of the most common human neoplasia BCC? From the mice model we have learned that the overexpression of SHH, the ligand for PTC, in the skin is sucient to have rapid and frequent BCC formation (Oro et al., 1997) suggesting that the disruption of the SHH ± PTC pathway is sucient per se to create BCC. In the present study molecular analysis of p53 and PTCH genes in the same BCC revealed that only 3/8 samples analysed were mutated in both tumor suppressor genes. No one was mutated exclusively in the p53 gene whereas 7/8 were mutated in the PTCH gene. In our previous study (D'Errico et al., 1997) in which we analysed p53 mutations and LOH of 9q22-31 (where the PTCH gene maps) in BCC from normal subjects, three of seven informative samples showed both p53 mutations and 9q loss. Tumor samples presenting either LOH at 9q or p53 mutation alone were also identi®ed. Our ®ndings appear to ®t into a model where a UV damage repair pathway defect in XP patients leads to a high level of UV-induced PTCH mutations. The consequent alteration of the SHH signaling pathway would result in the early and frequent appearance of BCC which is typical of XP patients. Conversely, in normal subjects the ecient removal of DNA photoproducts leads to an overall lower frequency of PTCH mutations by reducing those induced by UV light. This might account for the late onset of BCC and suggests that PTCH mutations might be an alternative pathway, apart from sunlight associated p53 mutations, in the development of this neoplasia.
